SpermCheck is Here!

February 21st, 2012 § 13 comments § permalink

SpermCheck has arrived and is filling the shelves of your neighborhood drug store as I write.  What is it?  It’s an over-the-counter FDA approved home male fertility test.  What does it do?  It tells you whether you have more than 20 million sperm per milliliter of semen.

That’s a good thing, right?  Generally, yes.  It’s good to know whether you have a reasonable amount of sperm, which SpermCheck says is 20 million per milliliter.  The problem is in the yes-or-no nature of the test and in picking the number 20 million.  As I described in this post, you can get a woman pregnant with sperm counts less than 20 million per milliliter and have problems with more than that amount.  The numbers of swimmers don’t tell the whole story.

So, will SpermCheck help you?  For most men, probably.  Having a positive or negative result will point them in the right direction.  But for the handful of guys that get the OK from the test when they have a problem or for those that get the thumbs-down from the test that are fertile, it’s not telling the whole story.  According to the manufacturer, the guys that are getting it wrong is about one in twenty.  If you’re OK with that, great–if not, you may want to see a doctor.

Taking Over the Pituitary

November 27th, 2011 § 19 comments § permalink

Bob recently asked about using hCG (human chorionic gonadotropin) rather than clomiphene to increase testosterone.  As I explained in How Clomid Works in Men, clomiphene stimulates the pituitary to make luteinizing hormone (LH), which then acts on the Leydig cells in the testis to make testosterone.  So why not use LH directly?

One way to take over the pituitary’s production of its reproductive hormones is to use human chorionic gonadotropin (hCG), which looks like LH to the body.  It effectively stimulates the Leydig cells to make testosterone.  But it’s expensive and must be injected.  So if the pituitary is working, clomiphene may be a better choice to start.  If the pituitary isn’t working, hCG can be tried.  But if the man’s LH is already very high, neither clomiphene or LH will help all that much, as the man’s body is already trying that strategy by itself.

The pituitary also makes follicle stimulating hormone (FSH), which acts on the Sertoli cells around the developing sperm cells.  To help stimulate the making of sperm in the testis, recombinant FSH (rFSH) or human menopausal gonadotropin (hMG) may be used.  Like hCG, these drugs are expensive and must be injected.

Thanks for the question, Bob!

Bike seat interview

November 25th, 2011 § 5 comments § permalink

Canadian television recently interviewed me on work in our bioengineering lab investigating how bicycle seats may cause problems with erections, and how current seats fall short in protecting men.  The interview may be viewed here.  It took place over Skype, and the sound quality is poor.  (I don’t really sound as if speaking through tissue paper.)

Fertility Preservation Options for Women

October 30th, 2011 § Comments Off on Fertility Preservation Options for Women § permalink

By Eve Feinberg, M.D.

As a fertility specialist, I see a wide variety of patients. In addition to infertile couples trying to achieve pregnancy, I see many single women interested in options for preserving fertility. With cancer therapies becoming even more successful in achieving cures, I also see a number of women with newly diagnosed cancer who are interested in fertility preservation options.

So…what are the different available options?

1) Oocyte vitrification “egg freezing”

Vitrification is a freezing method that encases a cell in a glass like (vitreo = glass in Latin) ball of ice. Vitrification does not cause ice crystal formation and therefore causes less damage to a cell. The egg is the largest single cell in the female body and the DNA contained inside the egg is especially sensitive to ice crystal formation. With the advent of vitrification technology, oocyte vitrification has rapidly advanced. Recent studies have shown that pregnancy rates from oocyte vitrification are almost comparable to pregnancy rates from traditional in-vitro fertilization (IVF).

The eggs are harvested in the same manner as if a woman was undergoing IVF. Injectable hormones are self-administered over a period of 1-2 weeks to stimulate the ovaries to produce eggs. During this time, a woman’s ovaries are monitored with almost daily transvaginal ultrasounds and blood estrogen levels. The ovaries respond to the medication by developing large follicles. Follicles are fluid filled spaces that contain an egg. When the follicles measure 16-20mm in size, another hormone is given to allow the egg to fully mature. 36-38 hours after this last shot is administered, the woman is put to sleep and the eggs are extracted from the ovaries using a transvaginal ultrasound with a needle attached. The needle goes through the vagina and into the ovary to remove the eggs. The eggs are passed off to an embryologist for inspection and rapid vitrification. The egg retrieval procedure only takes 15-20 minutes. Vitrified eggs can remain in storage for as little as a few hours or as long as a few years. When a woman is interested in using her eggs, they would be warmed and then inseminated with sperm. The day after insemination, the embryologist would check to see if the egg fertilized and then would allow the fertilized egg (now considered an embryo) to grow and develop in the laboratory for 3-5 days. The embryo or embryos would then be transferred back to the woman’s uterus. Nine to 11 days later, if pregnant, a blood pregnancy test would be positive.

Oocyte vitrification is an emerging option for fertility preservation in single women who wish to delay childbearing and in single women faced with a cancer diagnosis. For women with breast cancer, there are medications that can be given while stimulation is occurring to prevent estrogen levels from getting too high. Studies have demonstrated the safety of oocyte vitrification in cancer patients and have not shown earlier recurrence or worsening of survival rates. Another novel use of oocyte vitrification is in the arena of oocyte donation. Currently, nearly all oocyte donation cycles are fresh donations from an egg donor undergoing stimulation. It is realistic that in the next few years that egg donors may be able to undergo ovarian stimulation and eggs frozen well in advance of the time that they are going to be used. It is likely that egg banks will be established and prove a viable option for couples . It is also likely that women in their 20’s and early 30’s will be able to successfully bank eggs for the future to intentionally delay childbearing.

2) Embryo vitrification

Embryo vitrification is the best available technology for fertility preservation because. A vitrified embryo can remain in storage for 5-10 years and has an incredibly high likelihood of survival and pregnancy. For cancer patients who are married or are in a stable long-term relationship, embryo vitrification is the treatment of choice. Embryo vitrification is also a viable technique for single women who desire children, but wish to delay childbearing. A sperm source is needed and could be obtained from an anonymous sperm donor (most common) or from a known sperm donor (less common). Anonymous donor sperm is readily available through a sperm bank. A woman’s eggs are harvested in the same manner as for oocyte vitrification. Rather than the oocyte being passed off to the embryologist and vitrified, the oocyte is passed off to the embryologist and fertilized with sperm. The embryo grows in the laboratory until it is suitable for vitrification. The point in time at which vitrification happens differs by lab. Some labs choose to vitrify at the pronuclear stage, some at the day 3 stage and others at the blastocyst stage (days 5 or 6).

Embryo vitrification has the highest success rate of any treatment, but requires a sperm source. For a woman who prefers to leave her options open with regard to sperm source, other methods of fertility preservation may be more desirable

3) Ovarian cryopreservation

This technique requires removal of an ovary and freezing strips of the ovary for the future. These ovarian strips would later be thawed and re-implanted into a woman so that fertility could be restored. Of all technologies, this is considered to be the most experimental and has the fewest numbers of children born to date. There have, however, been a number of case reports of healthy children born from ovarian cryopreservation. This is a good option for a cancer patient who does not have the time to undergo ovarian stimulation for either oocyte or embryo vitrification.

Fertility preservation is an emerging area of reproductive endocrinology that empowers women to make fertility sparing choices when faced with a cancer diagnosis or when faced with the aging process without the immediate desire to become pregnant.

PSA and Prostate Cancer Interview

October 7th, 2011 § Comments Off on PSA and Prostate Cancer Interview § permalink

The U.S. Preventative Health Task Force is issuing guidelines today about the blood test PSA and its use in screening for diagnosis.  While I respect those doctors involved in making the guidelines, I don’t entirely agree that PSA shouldn’t ever be used.  ABC Chicago interviewed me this morning, and the segment can be found here.